» Articles » PMID: 6684983

Treatment of Six Cases of Mesothelioma with Doxorubicin and Cisplatin

Overview
Journal Cancer
Publisher Wiley
Specialty Oncology
Date 1983 Nov 15
PMID 6684983
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Six patients with unresectable malignant mesothelioma were treated with chemotherapy consisting of doxorubicin and cisplatin every 3 weeks. One patient with paratesticular mesothelioma metastatic to lungs entered complete remission for 8 months; his disease has relapsed but he is alive 32 months after initiation of chemotherapy. One patient with peritoneal mesothelioma achieved partial response for 12 months. Two patients with pleural mesothelioma achieved a partial response of 5- and 6-month durations, respectively. Two patients with pleural mesothelioma failed to respond to this regimen. Thus, four of six patients responded to doxorubicin-cisplatin chemotherapy. These preliminary results merit further study and confirmation; future investigations of cisplatin alone are necessary to better define the role of this agent in mesothelioma.

Citing Articles

Mesothelioma of the Tunica Vaginalis Testis: Diagnostic and Therapeutic Management. A Comprehensive Review, 1982-2024.

Stella S, Ceresoli G, Dallari B, Barile R, Maisenti F, Rugarli S Cancers (Basel). 2024; 16(23).

PMID: 39682143 PMC: 11639812. DOI: 10.3390/cancers16233956.


Development and In-Vitro Evaluation of Doxorubicin-Loaded Methacrylate Gelatin (GelMa)-Acrylamide Hydrogels for the Treatment of Malignant Pleural Mesothelioma.

Kulkarni N, Chauhan G, Quadros M, Gadhave D, Gupta V Pharm Res. 2024; 41(12):2331-2345.

PMID: 39633081 DOI: 10.1007/s11095-024-03794-z.


Asbestos exposure and malignant mesothelioma of the tunica vaginalis testis: a systematic review and the experience of the Apulia (southern Italy) mesothelioma register.

Vimercati L, Cavone D, Delfino M, De Maria L, Caputi A, Ferri G Environ Health. 2019; 18(1):78.

PMID: 31470859 PMC: 6717382. DOI: 10.1186/s12940-019-0512-4.


Preclinical studies identify novel targeted pharmacological strategies for treatment of human malignant pleural mesothelioma.

Favoni R, Daga A, Malatesta P, Florio T Br J Pharmacol. 2012; 166(2):532-53.

PMID: 22289125 PMC: 3417486. DOI: 10.1111/j.1476-5381.2012.01873.x.


Peritoneal mesothelioma.

Mohamed F, Sugarbaker P Curr Treat Options Oncol. 2002; 3(5):375-86.

PMID: 12194803 DOI: 10.1007/s11864-002-0003-6.